Mighty Therapeutics rebrands after FDA approval of FORZINITY (opens in new tab)

Stealth BioTherapeutics Holdings Inc. announced it will operate as Mighty Therapeutics, reflecting its transition to a commercial-stage biotechnology company focused on mitochondrial medicine. The rebrand follows the U.S. Food and Drug Administration’s accelerated approval and the commercial launch of FORZINITY (elamipretide) injection for patients weighing at least 30 kg with Barth syndrome. The company describes […] The post appeared first on <a href="